<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE resolution PUBLIC "-//US Congress//DTDs/res.dtd//EN" "res.dtd">
<resolution public-private="public" resolution-stage="Agreed-to-Senate" resolution-type="senate-resolution" star-print="no-star-print">
	<form>
		<distribution-code display="yes">III</distribution-code>
		<congress display="yes">109th CONGRESS</congress>
		<session display="yes">2d Session</session>
		<legis-num>S. RES. 560</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action display="yes">
			<action-date date="20060907" legis-day="20060906">September 7
			 (legislative day, September 6), 2006</action-date>
			<action-desc><sponsor name-id="S291">Mr. Coleman</sponsor> (for
			 himself, <cosponsor name-id="S274">Mr. Allen</cosponsor>,
			 <cosponsor name-id="S264">Mr. Bayh</cosponsor>, <cosponsor name-id="S249">Mr.
			 Brownback</cosponsor>, <cosponsor name-id="S277">Mr. Carper</cosponsor>,
			 <cosponsor name-id="S272">Mr. Chafee</cosponsor>, <cosponsor name-id="S136">Mr.
			 Cochran</cosponsor>, <cosponsor name-id="S252">Ms. Collins</cosponsor>,
			 <cosponsor name-id="S287">Mr. Cornyn</cosponsor>, <cosponsor name-id="S221">Mrs. Feinstein</cosponsor>, <cosponsor name-id="S293">Mr.
			 Graham</cosponsor>, <cosponsor name-id="S118">Mr. Hatch</cosponsor>,
			 <cosponsor name-id="S305">Mr. Isakson</cosponsor>, <cosponsor name-id="S257">Mr. Johnson</cosponsor>, <cosponsor name-id="S173">Mr.
			 Kerry</cosponsor>, <cosponsor name-id="S210">Mr. Lieberman</cosponsor>,
			 <cosponsor name-id="S269">Mrs. Lincoln</cosponsor>, <cosponsor name-id="S306">Mr. Menendez</cosponsor>, <cosponsor name-id="S182">Ms.
			 Mikulski</cosponsor>, <cosponsor name-id="S288">Ms. Murkowski</cosponsor>,
			 <cosponsor name-id="S229">Mrs. Murray</cosponsor>, <cosponsor name-id="S259">Mr. Reed</cosponsor>, <cosponsor name-id="S297">Mr.
			 Salazar</cosponsor>, <cosponsor name-id="S244">Mr. Santorum</cosponsor>,
			 <cosponsor name-id="S106">Mr. Sarbanes</cosponsor>, <cosponsor name-id="S270">Mr. Schumer</cosponsor>, <cosponsor name-id="S284">Ms.
			 Stabenow</cosponsor>, <cosponsor name-id="S286">Mr. Talent</cosponsor>, and
			 <cosponsor name-id="S271">Mr. Voinovich</cosponsor>) submitted the following
			 resolution; which was considered and agreed to</action-desc>
		</action>
		<legis-type>RESOLUTION</legis-type>
		<official-title display="yes">Supporting efforts to increase childhood
		  cancer awareness, treatment, and research.</official-title>
	</form>
	<preamble>
		<whereas><text>Whereas an estimated 12,400 children will be diagnosed
			 with cancer in the year 2005;</text>
		</whereas><whereas><text>Whereas cancer is the leading cause of death by disease in
			 children under age 15;</text>
		</whereas><whereas><text>Whereas an estimated 2,300 children will die from cancer
			 in the year 2005;</text>
		</whereas><whereas><text>Whereas the incidence of cancer among children in the
			 United States is rising by about one percent each year;</text>
		</whereas><whereas><text>Whereas 1 in every 330 Americans develops cancer before
			 age 20;</text>
		</whereas><whereas><text>Whereas approximately 8 percent of deaths of those between
			 1 and 19 years of age are caused by cancer;</text>
		</whereas><whereas><text>Whereas while some progress has been made, a number of
			 funding opportunities for childhood cancer research still remain;</text>
		</whereas><whereas><text>Whereas increasing the focus on childhood cancer research
			 requires the recruitment of additional investigators and physicians to
			 pediatric oncology;</text>
		</whereas><whereas><text>Whereas peer-reviewed clinical trials are the standard of
			 care for pediatrics and have improved cancer survival rates among
			 children;</text>
		</whereas><whereas><text>Whereas the number of survivors of childhood cancer
			 continues to grow, with about 1 in 640 adults between the ages of 20 and 39
			 having a history of cancer;</text>
		</whereas><whereas><text>Whereas up to <fraction>2/3</fraction> of childhood cancer
			 survivors are likely to experience at least one late effect from treatment,
			 many of which may be life-threatening;</text>
		</whereas><whereas><text>Whereas some late effects of cancer treatment are
			 identified early in follow-up and are easily resolved, while others may become
			 chronic problems in adulthood and may have serious consequences; and</text>
		</whereas><whereas><text>Whereas 89 percent of children with cancer experience
			 substantial suffering in the last month of life: Now, therefore, be it</text>
		</whereas></preamble>
	<resolution-body>
		<section commented="no" display-inline="yes-display-inline" id="idB1EAF56418AA4B42A3D4A4B4BC631F7F" section-type="undesignated-section"><enum></enum><text display-inline="yes-display-inline">That it is the sense of the Senate that
			 Congress should support—</text>
			<paragraph commented="no" display-inline="no-display-inline" id="H709F6690B82F4B3ABD9724D0F4AFD402"><enum>(1)</enum><text display-inline="yes-display-inline">public and private sector efforts to
			 promote awareness about the incidence of cancer among children, the signs and
			 symptoms of cancer in children, treatment options, and long-term
			 follow-up;</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H16992F3BB3604F74B7D0B01BC8E45050"><enum>(2)</enum><text display-inline="yes-display-inline">public and private investment in childhood
			 cancer research to improve prevention, diagnosis, treatment, rehabilitation,
			 post-treatment monitoring, and long-term survival;</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H8EE8E677ADDD4D1DB72636174CC00023"><enum>(3)</enum><text display-inline="yes-display-inline">medical trainees and investigators in the
			 field of pediatric oncology;</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H2D3CA200111A4E5E9F89D99597CBABA7"><enum>(4)</enum><text display-inline="yes-display-inline">policies that provide incentives to
			 encourage the development of drugs and biologics designed to treat pediatric
			 cancers;</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="HB554B56965C04C34A956C4640E29C63"><enum>(5)</enum><text display-inline="yes-display-inline">policies that encourage participation in
			 clinical trials;</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H2C85BDAA5BA44C3288E8D6DBCCAA9234"><enum>(6)</enum><text display-inline="yes-display-inline">medical education curricula designed to
			 improve pain management for cancer patients; and</text>
			</paragraph><paragraph commented="no" display-inline="no-display-inline" id="HA0B4DFCECC12466F94E97017B050DFDD"><enum>(7)</enum><text display-inline="yes-display-inline">policies that enhance education, services,
			 and other resources related to late effects from treatment.</text>
			</paragraph></section></resolution-body>
</resolution>
